China Health Holding Closes Acquisition 60% of Henan Furen Huaiqingtang Pharmaceutical Co. Ltd.

LAS VEGAS -- Julianna Lu, President/CEO of China Health Holding, Inc. (OTCBB:CHHH), a developer, marketer and manufacturer of natural herbal supplement products based on traditional Chinese medicine, announced today CHHH closes and executes ACQUISITIONS DEFINITIVE AGREEMENT with Mr. Zhu, WenChen, Chairman of Board and HENAN FUREN Pharmaceuticals Group Co. Ltd for acquisition 60% of Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd. (HFHT), a controlled-owned-subsidiary by Henan Furen Pharmaceuticals Group Co. Ltd.

CHHH agreed to pay $95 million (RMB) for completing transaction to acquire 60% of HFHT with approximately $100 million RMB worth of total assets, and approximately $110 million RMB annual gross revenues, and China-FDA Certified Pharmaceutical Drug GMP Manufacturing Facilities, with approximately a total lands positions of 2,800 square meters, and a total of 11,500 square meters buildings and facilities, based in ZhengZhou, PR China. HFHT has a total Forty-Six (46) China-FDA Certified Pharmaceutical Drug Pipeline which are fully distributing into China-FDA Licensed Hospitals and Drugs Stores across Henan province and Across PR China. HFHT's total 46 pharmaceutical injections drugs are specialized in medical treatments as Anti-Cancers drugs, Antibiotics drugs, Local Anaesthetics drugs, and Leukemia drugs, Dermatosis drugs, Analgesic drugs, Anticoagulants drug, Immunomodulator Drug, Cerebrovascular drugs, Antipyretics-analgesic and anti-inflammatory drugs, Thrombolytic drugs, Antimemic drugs, Cholinoceptor-blocking drugs, Digestion system drugs, Histamine Activator drug, Antifibrinolytics drugs, Hematonosis drugs,etc.

Further integration of transaction completion upon full due diligence satisfaction, CHHH intend to create incremental value from the acquisition of HPHT. By the end of the coming fourth quarter 2006 approximately, CHHH will recognize contribution from HPHT and expect the business to positively impact our reported results and the acquisition will contribute positively to both revenue and earnings power and assets. By acquiring HFHT we will obtain established China-FDA Certified Pharmaceutical Drug GMP manufacturing Facilities and an extensive hospitals and drugs stores distribution channel in China and an enhanced 46 China-FDA Certified Pharmaceutical Injections Drugs Pipeline. From a strategic perspective, this acquisition saves both time and money as it would have required substantial time and capital investment if we were to build such China-FDA certified Pharmaceutical Drug Facilities and 46 China-FDA Licensed Approved Pharmaceutical Drugs Pipeline and across China hospitals and drugs network from the ground up.

About China Health Holding, Inc.

China Health Holding, Inc., has an extensive knowledge of and expertise in the field of Traditional Chinese Medicine, which it uses to develop, manufacture, and commercialize natural herbal medicinal products and a comprehensive line of completely natural multi-vitamins and mineral food supplements. The Company's medicinal philosophy includes elements of traditional Taoist teachings and medical research related to the "King of Herbs" and significant herbal plants and minerals.

CHHH's immediate goal is profitable penetration of the growing global and China pharmaceutical industry and market and to seek and develop potential acquisition candidates with major pharmaceutical companies in PR China and worldwide to secure a strong future and powerful position in the global and PR China pharmaceutical industry. Long-term plans include the development of a pharmaceutical drug pipeline and technology based on the Company's access to the knowledge of Traditional Chinese Medicine and PR China pharmaceutical industry.

CHHH is supported by two core, wholly owned subsidiaries:

1.China Health World Pharmaceutical Corporation, which develops, manufactures and commercializes natural medications for epidemic diseases and conditions related to mellitus, cardiovascular and cerebral-vascular system dysfunctions, and neurological disorders.

2.China Health World Trade Corporation, which supports CHHH in the areas of worldwide branding, multimedia marketing and multi-channel distribution to global customers and markets.

Recent Developments:

CHHH recently entered into letters of intent to acquire 51% or more of four pharmaceutical companies in PR China, as follows:

--Shaanxi Wanan Pharmaceutical Co. Ltd.

--Henan Tiankang Pharmaceuticals Co. Ltd.

--Shaanxi Meichen Pharmaceuticals Co. Ltd.

CHHH has completed Acquisitions Definitive Agreement to acquire 60% of Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd.

CHHH believes that further acquisitions will enable it to vertically integrate its operations from manufacturing, developing and marketing Chinese herbal based medicinal products, as well as a pharmaceutical drug pipeline, to full distribution and marketing across PR China, therefore substantially increasing profit margins. Acquisitions should accelerate growth of revenues and earnings. A strategic combination of assets, net income, an enhanced pharmaceutical drug pipeline and technologies will accrete value to the Company and its shareholders.

CHHH recently signed a letter of intent with WangJing Hospital and the WangJing Hospital of China Academy of Chinese Medical Sciences, PR China, in order to develop the China International University of Traditional Chinese Medicine and the University Hospital for Traditional Chinese Medical Sciences.

Safe Harbor 

To the extent that statements in the press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, all forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements, which may accompany the forward-looking statements, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Other important factors that could cause actual results to differ materially include the following: business conditions and the amount of growth in the Company's industry and general economy; competitive factors; ability to attract and retain personnel; the price of the Company's stock; and the risk factors set forth from time to time in the Company's SEC reports, including but not limited to its annual report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and any reports on Form 8-K. In addition, the company disclaims any obligation to update or correct any forward-looking statements in all of the Company's press releases to reflect events or circumstances after the date hereof.